Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects
Status:
Completed
Trial end date:
2018-10-01
Target enrollment:
Participant gender:
Summary
This is a non-randomized, open-label Phase 1b trial to establish the safety and recommended
phase 2 dose (RP2D) of bavituximab in combination with pemetrexed and carboplatin in subjects
with previously untreated stage IV non-squamous non-small cell lung cancer (NSCLC).